Free Trial
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel
NASDAQ:VRDN

Viridian Therapeutics Q3 2026 Earnings Date & Estimates

Viridian Therapeutics logo
$18.34 +0.06 (+0.33%)
Closing price 10/8/2026 04:00 PM Eastern
Extended Trading
$18.50 +0.16 (+0.85%)
As of 05:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Viridian Therapeutics is expected to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Viridian Therapeutics in Q3 2026

Viridian Therapeutics is expected to post earnings of -$0.99 per share on revenue of $4.58 million. In the same quarter a year earlier Viridian Therapeutics reported -$0.34 per share on revenue of $70.57 million. Viridian Therapeutics last reported on August 6, 2026, posting -$1.05 per share and missing the -$1.03 consensus estimate. Viridian Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.99
Expected Revenue
$4.58 million
Prior-Year EPS
-$0.34
Prior-Year Revenue
$70.57 million
Expected Revenue Growth
-93.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.05 (Missed by -$0.02)
Last Quarter Revenue
$0.28 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Viridian Therapeutics Q3 2026 Earnings FAQ

Viridian Therapeutics (NASDAQ:VRDN) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Viridian Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Viridian Therapeutics to post earnings of -$0.99 per share for Q3 2026.

The consensus revenue estimate for Viridian Therapeutics is $4.58 million for Q3 2026.

Viridian Therapeutics Earnings Headlines

Viridian Therapeutics (NASDAQ:VRDN) versus Revolution Medicines (NASDAQ:RVMD) Financial Contrast
October 7 at 4:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095247
Emergent Biosolutions (NYSE:EBS) and Viridian Therapeutics (NASDAQ:VRDN) Head to Head Contrast
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31084125
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
 |  Banyan Hill Publishing (Ad)
Wall Street Zen Downgrades Viridian Therapeutics (NASDAQ:VRDN) to Strong Sell
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083564
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Brokerages
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068783
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (VRDN)
September 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VRDN/pressreleases/4751859/analysts-opinions-are-mixed-on-these-healthcare-stocks-cvrx-cvrx-butterfly-network-bfly-and-viridian-therapeutics-vrdn/
See More Viridian Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Viridian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viridian Therapeutics and other key companies, straight to your email.

About Viridian Therapeutics

Viridian Therapeutics (NASDAQ:VRDN) (NASDAQ:VRDN) is a clinical-stage biotechnology company focused on developing treatments for autoimmune and inflammatory diseases. The company’s primary research centers on antibody-based medicines designed to target the insulin-like growth factor 1 receptor (IGF-1R), a biological pathway associated with thyroid eye disease (TED).

Viridian’s pipeline includes veligrotug, an investigational monoclonal antibody being developed for TED, as well as additional drug candidates intended to provide alternative dosing options and potentially address broader autoimmune conditions. The company has also explored subcutaneous formulations and longer-acting approaches designed to improve the convenience of treatment. Its candidates remain subject to clinical testing and regulatory review, and the company does not currently have a broadly marketed commercial product.

Founded in 2018, Viridian is headquartered in Waltham, Massachusetts. The company’s activities have focused on research, clinical development and regulatory advancement in the United States and other international markets through global clinical programs. Viridian is led by Chief Executive Officer Bill Lis.

View Viridian Therapeutics Profile
Earnings Tools